Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib

There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast g...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, Martin, Mellemgaard, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494183/
https://www.ncbi.nlm.nih.gov/pubmed/26170616
http://dx.doi.org/10.2147/BTT.S57356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494183/
https://www.ncbi.nlm.nih.gov/pubmed/26170616
http://dx.doi.org/10.2147/BTT.S57356

Ejemplares similares